Quarterly results

Latest results

2020 Full year and fourth quarter

Released 03 February 2021

We will announce our full year and fourth quarter 2020 results at 12:00 GMT, 07:00 EST on Wednesday 3 February 2021.

Following the announcement there will be a webcast hosted by Emma Walmsley, CEO, Iain Mackay, CFO and Dr Hal Barron, Chief Scientific Officer and President of R&D at 14:00 GMT, 09:00 EST.

2012 Fourth Quarter - released 06 February 2013
Released 06 February 2013
Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.
- View the press release
Key highlights
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
Related downloads
2012 Third Quarter - released 31 October 2012
Released 31 October 2012
Simon Dingemans, CFO, discusses our Q3 results 2012.
Key highlights
- Core EPS of 26.5p
- Dividend of 18p (+ 6%)
- Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
- Continued strong cash generation and returns to shareholders
Related downloads
2012 Second Quarter - released 25 July 2012
Released 25 July 2012
Watch Sir Andrew Witty, CEO, discuss our second quarter results 2012.
- View the press release
Key highlights
- Core EPS of 26.4p
- Dividend of 17p (up 6%)
- Significant late-stage pipeline delivery
Related downloads
2012 First Quarter - released 25 April 2012
Released 25 April 2012
Watch Simon Dingemans, CFO, discuss our first quarter results 2012.
Key highlights
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
Related downloads